These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 27329844)

  • 21. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
    Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Ju HQ; Zhan G; Huang A; Sun Y; Wen S; Yang J; Lu WH; Xu RH; Li J; Li Y; Garcia-Manero G; Huang P; Hu Y
    Leukemia; 2017 Oct; 31(10):2143-2150. PubMed ID: 28194038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
    Shankar DB; Li J; Tapang P; Owen McCall J; Pease LJ; Dai Y; Wei RQ; Albert DH; Bouska JJ; Osterling DJ; Guo J; Marcotte PA; Johnson EF; Soni N; Hartandi K; Michaelides MR; Davidsen SK; Priceman SJ; Chang JC; Rhodes K; Shah N; Moore TB; Sakamoto KM; Glaser KB
    Blood; 2007 Apr; 109(8):3400-8. PubMed ID: 17209055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
    Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
    Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK; Grundler R; Peschel C; Duyster J
    Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
    Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
    Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y; Sun L; Xu Y; Fu L; Li Y; Bao X; Fu H; Xie C; Lou L
    Cancer Lett; 2018 Apr; 420():49-59. PubMed ID: 29409989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.
    Chang YT; Hernandez D; Alonso S; Gao M; Su M; Ghiaur G; Levis MJ; Jones RJ
    Blood Adv; 2019 Mar; 3(6):908-916. PubMed ID: 30898762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
    Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
    Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
    Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H
    Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
    Kowolik CM; Lin M; Xie J; Overman LE; Horne DA
    Oncotarget; 2016 Dec; 7(52):86186-86197. PubMed ID: 27863389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
    Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
    Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
    Scarpa M; Singh P; Bailey CM; Lee JK; Kapoor S; Lapidus RG; Niyongere S; Sangodkar J; Wang Y; Perrotti D; Narla G; Baer MR
    Mol Cancer Ther; 2021 Apr; 20(4):676-690. PubMed ID: 33568357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.